Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival

Metabolic imaging reveals anti-angiogenic (AA) therapy mechanisms in glioblastoma (GBM) GBM is the most common and aggressive type of malignant primary brain tumors (glioma). Patients with GBM have less than 5% survival at 5 years with the best existing treatment and progress is desperately needed t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ovidiu C. Andronesi, Morteza Esmaeili, Ronald J. H. Borra, Kyrre Emblem, Elizabeth R. Gerstner, Marco C. Pinho, Scott R. Plotkin, Andrew S. Chi, April F. Eichler, Jorg Dietrich, S. Percy Ivy, Patrick Y. Wen, Dan G. Duda, Rakesh Jain, Bruce R. Rosen, Gregory A. Sorensen, Tracy T. Batchelor
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/cff8891abc634b19b196fe665c1e1ac0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cff8891abc634b19b196fe665c1e1ac0
record_format	dspace
spelling	oai:doaj.org-article:cff8891abc634b19b196fe665c1e1ac02021-12-02T14:22:13ZEarly changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival10.1038/s41698-017-0020-32397-768Xhttps://doaj.org/article/cff8891abc634b19b196fe665c1e1ac02017-06-01T00:00:00Zhttps://doi.org/10.1038/s41698-017-0020-3https://doaj.org/toc/2397-768XMetabolic imaging reveals anti-angiogenic (AA) therapy mechanisms in glioblastoma (GBM) GBM is the most common and aggressive type of malignant primary brain tumors (glioma). Patients with GBM have less than 5% survival at 5 years with the best existing treatment and progress is desperately needed to improve patient outcome. Imaging can guide development and clinical translation of new treatments, and can help to understand mechanisms of response and to optimize drug regimens in patients. AA therapy that targets the blood supply of tumors can benefit GBM patients as adjuvant therapy to standard chemoradiation, but the timing of combination therapy may be important to obtain the maximum benefit and minimize negative side effects. Tracking metabolic changes with magnetic resonance spectroscopic imaging (MRSI) during a phase II clinical trial of AA drug cediranib combined with chemoradiation shows that there is a therapeutic window within the first month where there is maximal synergy between the effects of the anti-angiogenesis and chemoradiation. Our data suggest that adjusting the dose of AA therapy during chemoradiation may be beneficial, and MRSI can be used as a precision medicine tool to identify the patients and time for adjusting the combination treatment.Ovidiu C. AndronesiMorteza EsmaeiliRonald J. H. BorraKyrre EmblemElizabeth R. GerstnerMarco C. PinhoScott R. PlotkinAndrew S. ChiApril F. EichlerJorg DietrichS. Percy IvyPatrick Y. WenDan G. DudaRakesh JainBruce R. RosenGregory A. SorensenTracy T. BatchelorNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Precision Oncology, Vol 1, Iss 1, Pp 1-9 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Ovidiu C. Andronesi Morteza Esmaeili Ronald J. H. Borra Kyrre Emblem Elizabeth R. Gerstner Marco C. Pinho Scott R. Plotkin Andrew S. Chi April F. Eichler Jorg Dietrich S. Percy Ivy Patrick Y. Wen Dan G. Duda Rakesh Jain Bruce R. Rosen Gregory A. Sorensen Tracy T. Batchelor Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival
description	Metabolic imaging reveals anti-angiogenic (AA) therapy mechanisms in glioblastoma (GBM) GBM is the most common and aggressive type of malignant primary brain tumors (glioma). Patients with GBM have less than 5% survival at 5 years with the best existing treatment and progress is desperately needed to improve patient outcome. Imaging can guide development and clinical translation of new treatments, and can help to understand mechanisms of response and to optimize drug regimens in patients. AA therapy that targets the blood supply of tumors can benefit GBM patients as adjuvant therapy to standard chemoradiation, but the timing of combination therapy may be important to obtain the maximum benefit and minimize negative side effects. Tracking metabolic changes with magnetic resonance spectroscopic imaging (MRSI) during a phase II clinical trial of AA drug cediranib combined with chemoradiation shows that there is a therapeutic window within the first month where there is maximal synergy between the effects of the anti-angiogenesis and chemoradiation. Our data suggest that adjusting the dose of AA therapy during chemoradiation may be beneficial, and MRSI can be used as a precision medicine tool to identify the patients and time for adjusting the combination treatment.
format	article
author	Ovidiu C. Andronesi Morteza Esmaeili Ronald J. H. Borra Kyrre Emblem Elizabeth R. Gerstner Marco C. Pinho Scott R. Plotkin Andrew S. Chi April F. Eichler Jorg Dietrich S. Percy Ivy Patrick Y. Wen Dan G. Duda Rakesh Jain Bruce R. Rosen Gregory A. Sorensen Tracy T. Batchelor
author_facet	Ovidiu C. Andronesi Morteza Esmaeili Ronald J. H. Borra Kyrre Emblem Elizabeth R. Gerstner Marco C. Pinho Scott R. Plotkin Andrew S. Chi April F. Eichler Jorg Dietrich S. Percy Ivy Patrick Y. Wen Dan G. Duda Rakesh Jain Bruce R. Rosen Gregory A. Sorensen Tracy T. Batchelor
author_sort	Ovidiu C. Andronesi
title	Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival
title_short	Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival
title_full	Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival
title_fullStr	Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival
title_full_unstemmed	Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival
title_sort	early changes in glioblastoma metabolism measured by mr spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/cff8891abc634b19b196fe665c1e1ac0
work_keys_str_mv	AT ovidiucandronesi earlychangesinglioblastomametabolismmeasuredbymrspectroscopicimagingduringcombinationofantiangiogeniccediranibandchemoradiationtherapyareassociatedwithsurvival AT mortezaesmaeili earlychangesinglioblastomametabolismmeasuredbymrspectroscopicimagingduringcombinationofantiangiogeniccediranibandchemoradiationtherapyareassociatedwithsurvival AT ronaldjhborra earlychangesinglioblastomametabolismmeasuredbymrspectroscopicimagingduringcombinationofantiangiogeniccediranibandchemoradiationtherapyareassociatedwithsurvival AT kyrreemblem earlychangesinglioblastomametabolismmeasuredbymrspectroscopicimagingduringcombinationofantiangiogeniccediranibandchemoradiationtherapyareassociatedwithsurvival AT elizabethrgerstner earlychangesinglioblastomametabolismmeasuredbymrspectroscopicimagingduringcombinationofantiangiogeniccediranibandchemoradiationtherapyareassociatedwithsurvival AT marcocpinho earlychangesinglioblastomametabolismmeasuredbymrspectroscopicimagingduringcombinationofantiangiogeniccediranibandchemoradiationtherapyareassociatedwithsurvival AT scottrplotkin earlychangesinglioblastomametabolismmeasuredbymrspectroscopicimagingduringcombinationofantiangiogeniccediranibandchemoradiationtherapyareassociatedwithsurvival AT andrewschi earlychangesinglioblastomametabolismmeasuredbymrspectroscopicimagingduringcombinationofantiangiogeniccediranibandchemoradiationtherapyareassociatedwithsurvival AT aprilfeichler earlychangesinglioblastomametabolismmeasuredbymrspectroscopicimagingduringcombinationofantiangiogeniccediranibandchemoradiationtherapyareassociatedwithsurvival AT jorgdietrich earlychangesinglioblastomametabolismmeasuredbymrspectroscopicimagingduringcombinationofantiangiogeniccediranibandchemoradiationtherapyareassociatedwithsurvival AT spercyivy earlychangesinglioblastomametabolismmeasuredbymrspectroscopicimagingduringcombinationofantiangiogeniccediranibandchemoradiationtherapyareassociatedwithsurvival AT patrickywen earlychangesinglioblastomametabolismmeasuredbymrspectroscopicimagingduringcombinationofantiangiogeniccediranibandchemoradiationtherapyareassociatedwithsurvival AT dangduda earlychangesinglioblastomametabolismmeasuredbymrspectroscopicimagingduringcombinationofantiangiogeniccediranibandchemoradiationtherapyareassociatedwithsurvival AT rakeshjain earlychangesinglioblastomametabolismmeasuredbymrspectroscopicimagingduringcombinationofantiangiogeniccediranibandchemoradiationtherapyareassociatedwithsurvival AT brucerrosen earlychangesinglioblastomametabolismmeasuredbymrspectroscopicimagingduringcombinationofantiangiogeniccediranibandchemoradiationtherapyareassociatedwithsurvival AT gregoryasorensen earlychangesinglioblastomametabolismmeasuredbymrspectroscopicimagingduringcombinationofantiangiogeniccediranibandchemoradiationtherapyareassociatedwithsurvival AT tracytbatchelor earlychangesinglioblastomametabolismmeasuredbymrspectroscopicimagingduringcombinationofantiangiogeniccediranibandchemoradiationtherapyareassociatedwithsurvival
_version_	1718391517505126400

Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival

Ejemplares similares